These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24407918)

  • 21. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
    Yao J; Maxwell JB; Rock CO
    J Biol Chem; 2013 Dec; 288(51):36261-71. PubMed ID: 24189061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The X-ray structure of Escherichia coli enoyl reductase with bound NAD+ at 2.1 A resolution.
    Baldock C; Rafferty JB; Stuitje AR; Slabas AR; Rice DW
    J Mol Biol; 1998 Dec; 284(5):1529-46. PubMed ID: 9878369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor.
    Saito J; Yamada M; Watanabe T; Iida M; Kitagawa H; Takahata S; Ozawa T; Takeuchi Y; Ohsawa F
    Protein Sci; 2008 Apr; 17(4):691-9. PubMed ID: 18305197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dimeric and tetrameric forms of enoyl-acyl carrier protein reductase from Bacillus cereus.
    Kim SJ; Ha BH; Kim KH; Hong SK; Shin KJ; Suh SW; Kim EE
    Biochem Biophys Res Commun; 2010 Oct; 400(4):517-22. PubMed ID: 20800575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.
    Afanador GA; Muench SP; McPhillie M; Fomovska A; Schön A; Zhou Y; Cheng G; Stec J; Freundlich JS; Shieh HM; Anderson JW; Jacobus DP; Fidock DA; Kozikowski AP; Fishwick CW; Rice DW; Freire E; McLeod R; Prigge ST
    Biochemistry; 2013 Dec; 52(51):9155-66. PubMed ID: 24295325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A triclosan-resistance protein from the soil metagenome is a novel enoyl-acyl carrier protein reductase: Structure-guided functional analysis.
    Kim SH; Khan R; Choi K; Lee SW; Rhee S
    FEBS J; 2020 Nov; 287(21):4710-4728. PubMed ID: 32112503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunflower (Helianthus annuus) fatty acid synthase complex: enoyl-[acyl carrier protein]-reductase genes.
    González-Thuillier I; Venegas-Calerón M; Garcés R; von Wettstein-Knowles P; Martínez-Force E
    Planta; 2015 Jan; 241(1):43-56. PubMed ID: 25204631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do Go Chasing Waterfalls: Enoyl Reductase (FabI) in Complex with Inhibitors Stabilizes the Tetrameric Structure and Opens Water Channels.
    Maltarollo VG; Shevchenko E; Lima IDM; Cino EA; Ferreira GM; Poso A; Kronenberger T
    J Chem Inf Model; 2022 Nov; 62(22):5746-5761. PubMed ID: 36343333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.
    Hoang TT; Schweizer HP
    J Bacteriol; 1999 Sep; 181(17):5489-97. PubMed ID: 10464225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based drug design and in vitro testing reveal new inhibitors of enoyl-acyl carrier protein reductases.
    Ghattas MA; Eissa NA; Tessaro F; Perozzo R; Scapozza L; Obaid D; Atatreh N
    Chem Biol Drug Des; 2019 Aug; 94(2):1545-1555. PubMed ID: 31063658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methyl-branched fatty acids, inhibitors of enoyl-ACP reductase with antibacterial activity from Streptomyces sp. A251.
    Zheng CJ; Sohn MJ; Chi SW; Kim WG
    J Microbiol Biotechnol; 2010 May; 20(5):875-80. PubMed ID: 20519910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes.
    Yao J; Ericson ME; Frank MW; Rock CO
    Infect Immun; 2016 Dec; 84(12):3597-3607. PubMed ID: 27736774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'Candidatus Liberibacter americanus', associated with citrus huanglongbing (greening disease) in São Paulo State, Brazil.
    Teixeira DDC; Saillard C; Eveillard S; Danet JL; Costa PID; Ayres AJ; Bové J
    Int J Syst Evol Microbiol; 2005 Sep; 55(Pt 5):1857-1862. PubMed ID: 16166678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis.
    Yao J; Abdelrahman YM; Robertson RM; Cox JV; Belland RJ; White SW; Rock CO
    J Biol Chem; 2014 Aug; 289(32):22365-76. PubMed ID: 24958721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.
    Lu X; Lv M; Huang K; Ding K; You Q
    Int J Mol Sci; 2012; 13(6):6620-6638. PubMed ID: 22837653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
    Sivaraman S; Sullivan TJ; Johnson F; Novichenok P; Cui G; Simmerling C; Tonge PJ
    J Med Chem; 2004 Jan; 47(3):509-18. PubMed ID: 14736233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of substrate binding loop mutations on the structure, kinetics, and inhibition of enoyl acyl carrier protein reductase from Plasmodium falciparum.
    Maity K; Banerjee T; Prabakaran N; Surolia N; Surolia A; Suguna K
    IUBMB Life; 2011 Jan; 63(1):30-41. PubMed ID: 21280175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan.
    Priyadarshi A; Kim EE; Hwang KY
    Proteins; 2010 Feb; 78(2):480-6. PubMed ID: 19768684
    [No Abstract]   [Full Text] [Related]  

  • 40. Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality.
    Schiebel J; Chang A; Lu H; Baxter MV; Tonge PJ; Kisker C
    Structure; 2012 May; 20(5):802-13. PubMed ID: 22579249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.